Osmolex ER is a Small Molecule owned by Supernus Pharmaceuticals, and is involved in 1 clinical trial, which was completed.
Amantadine hydrochloride extended release elicits central nervous system activity. The drug candidate exhibits anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine. The drug candidate may cause greater amounts of dopamine to be released in the brain.
The revenue for Osmolex ER is expected to reach a total of $50m through 2033. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Osmolex ER NPV Report.
Osmolex ER is currently owned by Supernus Pharmaceuticals.
Osmolex ER Overview
Amantadine hydrochloride (Osmlex ER) is developed based on osmodex technology acts as anti parkinson's agent. It is formulated as extended release coated tablets for oral route of administration. Osmlex ER is indicated for the treatment of Parkinson's disease and for the treatment of drug-induced extrapyramidal reactions in adult patients.
Supernus Pharmaceuticals Overview
Supernus Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-812, SPN-817, and SPN-820. The company’s technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$579.8 million for the fiscal year ended December 2021 (FY2021), an increase of 11.4% over FY2020. In FY2021, the company’s operating margin was 14.8%, compared to an operating margin of 33.4% in FY2020. In FY2021, the company recorded a net margin of 9.2%, compared to a net margin of 24.4% in FY2020. The company reported revenues of US$170.1 million for the second quarter ended June 2022, an increase of 11.5% over the previous quarter.
Quick View – Osmolex ER
|Highest Development Stage|